Laboratory medicine · 2026
Utility of PAX1/JAM3 methylation analysis for triage of high-risk HPV-positive individuals.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Guo Qin, Wang Huaguo, Diao Xue, Liu Yinghong, Chen Yanling, Long Qiyun, Liu Zejiang, Qi Xing, Lin Sheng, Song Xuhui
Аннотация
INTRODUCTION: We sought to assess the clinical utility of methylation detection of paired box gene 1 (PAX1) and junctional adhesion molecule 3 (JAM3) in the triage of individuals testing positive for high-risk human papillomavirus (HPV).
METHODS: Cervical secretions from 312 high-risk HPV-positive patients were analyzed for dual-gene methylation of PAX1 and JAM3 (PAX1m/JAM3m). Methylation levels were compared across histologically confirmed cervical lesions. Using histopathology as the reference standard, the triage performance of PAX1m/JAM3m was evaluated against cytology and HPV-16/18 genotyping.
RESULTS: Methylation positivity increased in statistical significance with lesion severity (P < .001 for trend). For the detection of cervical intraepithelial neoplasia (CIN) 2 or more severe lesions (CIN2+), PAX1m/JAM3m yielded a sensitivity of 91.8% (95% CI, 84.1%-96.2%), specificity of 90.7% (95% CI, 85.7%-94.1%), and an area under the receiver operating characteristic curve of 0.912 (95% CI, 0.874-0.951), outperforming cytology, HPV-16/18 genotyping, and their combinations. Using PAX1m/JAM3m positivity as a criterion for colposcopy referral, 1 CIN2+ case was detected per 1.22 referrals, reducing the colposcopy referral rate by approximately 19.2% and increasing the CIN2+ detection rate by 39.4% compared with cytology at the atypical squamous cells of undetermined significance threshold.
DISCUSSION: PAX1m/JAM3m levels are strongly associated with cervical lesion severity and represent a promising triage strategy for high-risk HPV-positive individuals.
METHODS: Cervical secretions from 312 high-risk HPV-positive patients were analyzed for dual-gene methylation of PAX1 and JAM3 (PAX1m/JAM3m). Methylation levels were compared across histologically confirmed cervical lesions. Using histopathology as the reference standard, the triage performance of PAX1m/JAM3m was evaluated against cytology and HPV-16/18 genotyping.
RESULTS: Methylation positivity increased in statistical significance with lesion severity (P < .001 for trend). For the detection of cervical intraepithelial neoplasia (CIN) 2 or more severe lesions (CIN2+), PAX1m/JAM3m yielded a sensitivity of 91.8% (95% CI, 84.1%-96.2%), specificity of 90.7% (95% CI, 85.7%-94.1%), and an area under the receiver operating characteristic curve of 0.912 (95% CI, 0.874-0.951), outperforming cytology, HPV-16/18 genotyping, and their combinations. Using PAX1m/JAM3m positivity as a criterion for colposcopy referral, 1 CIN2+ case was detected per 1.22 referrals, reducing the colposcopy referral rate by approximately 19.2% and increasing the CIN2+ detection rate by 39.4% compared with cytology at the atypical squamous cells of undetermined significance threshold.
DISCUSSION: PAX1m/JAM3m levels are strongly associated with cervical lesion severity and represent a promising triage strategy for high-risk HPV-positive individuals.